Oragenics announced its lead candidate for treating concussion, ONP-002, is stable across a wide temperature range, eliminating the need for cumbersome cold storage for the drug device combination. ONP-002 is a new chemical entity designed to target the brain through a breath propelled delivery system into the nasal cavity to treat concussions. Oragenics recently completed the synthesis of its ONP-002 drug batch for the planned Phase II clinical trial. The company reports 3-month stability with over 99% purity at temperatures ranging from -20 degrees C to 104 degrees C. Oragenics is confident in its belief that ONP-002 will not require cumbersome cold chain protocols during transport and storage, maintaining its chemical structure and function even in extreme temperatures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
- Oragenics announces ONP-002 completes FDA-required Genotoxicity Study
- Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
- Oragenics announces concussion drug ONP-002 clears cardiotoxicity testing
- Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing